

**How well do  
treatments prevent  
COVID  
shingles  
heart disease  
diabetes  
or anything else  
that might ail you?**




**James McCormack**

BSc (Pharm), PharmD

Professor

University of British Columbia

Vancouver, BC, Canada



# Objectives

- To explain my philosophy on treatments
- To be skeptical when it comes to medical information
- To realise you need to know the “numbers” - at least a ballpark idea
- To have you understand the benefit of preventative treatments such as the COVID vaccine, the shingles vaccine, blood pressure/glucose/cholesterol treatments



# My Specific Philosophy on Medications

(anything that is not food, surgery, talk or physical manipulation)



Some medications are incredibly useful



Most medications don't work nearly as well as you think



Most new medications are no better than what we  
already have



Most of the starting doses in the medication books are  
**TOO HIGH**

# My Simple Philosophy on Treatments



These sorts of terms are uniformly uninformative - allopathic, conventional, mainstream, Western medicine, complementary, alternative, integrative, naturopathy, Chinese medicine, homeopathy, herbal




We all treat people with “things” - oral/injections/topical, nutrition, surgery, talk, physical manipulations etc




I don't care HOW treatments work, I care IF treatments work

# How Does It Work?



Nice to Know




**Absolutely !@#\$\$ Crucial to Know**

# My Simple Philosophy on Treatments



IMHO there are only 2 classes of treatments - those that have been shown to work (or not work) and those that haven't been properly studied



Ever wonder  
if the  
recommendations  
from these shows  
are evidence-based?  
**WE DID**



## Televised medical talk shows—what they recommend and the evidence to support their recommendations: a prospective observational study

 OPEN ACCESS

**thebmj** 2014

Christina Korownyk *associate professor of family medicine*<sup>1</sup>, Michael R Kolber *associate professor of family medicine*<sup>1</sup>, James McCormack *professor of pharmacy*<sup>3</sup>, Vanessa Lam *research assistant*<sup>2</sup>, Kate Overbo *research assistant*<sup>2</sup>, Candra Cotton *pharmacist*<sup>1</sup>, Caitlin Finley *research assistant*<sup>1</sup>, Ricky D Turgeon *pharmacist*<sup>3</sup>, Scott Garrison *associate professor of family medicine*<sup>1</sup>, Adrienne J Lindblad *associate clinical professor of family medicine*<sup>1</sup>, Hoan Linh Banh *associate professor of family medicine*<sup>1</sup>, Denise Campbell-Scherer *associate professor of family medicine*<sup>1</sup>, Ben Vandermeer *biostatistician*<sup>4</sup>, G Michael Allan *professor of family medicine*<sup>1</sup>

Brit Med J 2014;349:g7346 doi: 10.1136/bmj.g7346 (Published 17 December 2014)

# “Believable” Evidence for Recommendations

	EVIDENCE			
	Supports	Contradicted	Not Found	Believable or somewhat believable
Dr Oz	46%	15%	39%	33%
The Doctors	63%	14%	24%	53%



World Health  
Organization



**300+**  
**medications**

**40**

Years of the Model List  
of Essential Medicines

1977 - 2017

Most new things aren't  
much or any better



# Golden Pill Award

**PRESCRIBE AWARDS**

	Major advance (1)	Clear advance (7)	Modest improvement (13)
2011	0	0	0
2012	0	0	2 abiraterone (prostate CA), boceprevir (Hep C)
2013	0	0	1 meningococcal conjugate vaccine (infant immunization)
2014	1 cholic acid (hereditary bile acid deficiency)	3 imatinib (ALL), artesunate (malaria), sofosbuvir (HepC)	1 sodium phenylbutyrate coated granules (urea cycle disorders)
2015	0	1 propranolol (severe infantile hemangioma)	2 permethrin (scabies), ketoconazole HRA (endogenous Cushing's syndrome)
2016	0	0	2 nivolumab (inoperable melanoma), trametinib (inoperable melanoma)
2017	0	1 asfotase alfa (perinatal and infantile forms of hypophosphatasia)	2 pertuzumab (metastatic breast cancer), emtricitabine/tenofovir (HIV transmission)
2018	0	2 sebelipase alfa (lysosomal acid lipase deficiency), naloxone nasal spray (emergency treatment of opioid overdose)	3 lidocaine + prilocaine combination (primary premature ejaculation), naloxone IM kit (emergency treatment of opioid overdose), arsenic trioxide (acute promyelocytic leukaemia)
2019	0	3 emicizumab (prophylaxis of bleeding episodes in patients with haemophilia A and "factor VIII inhibitors"), tisagenlecleucel (B-cell acute lymphoblastic leukaemia), axicabtagene ciloleucel (large B-cell lymphomas)	3 ruxolitinib (symptomatic myelofibrosis), trastuzumab emtansine (HER2-positive inoperable breast cancer), pembrolizumab (metastatic non-small cell lung cancer)



**IMPORTANT  
ANNOUNCEMENT!**

elevated blood pressure  
elevated cholesterol  
elevated glucose (type 2 diabetes)

for almost all people  
these are risk factors  
**NOT** diseases

# Risk Factors versus Clinical Endpoints

“a risk factor/marker is a variable associated with an increased risk of disease”

Surrogate Markers -Not As Important	Outcomes you can feel - Very Important
blood pressure	symptoms
cholesterol	heart attacks
glucose/diabetes	strokes
bone density	heart failure
heart rate	death
CRP	dialysis
proteinuria	amputation
FEV1	fractures
	blindness
	revascularization
	angina
	TIAs

# Surrogates

## The Never-ending Consistently Inconsistent Story

### **LIPIDS**

HDL - torcetrapib ↑ HDL and ↓ LDL → CVD and mortality ↑

LDL - niacin and ezetimibe ↓ LDL → no change in outcomes

Trigs - fibrates ↓ trigs → no change in outcomes

### **BLOOD PRESSURE**

Atenolol, aliskiren, doxazosin ↓ BP → no change in outcomes

### **GLUCOSE (A1c)**

Most medications that ↓ glucose → no change or ↑ outcomes

### **ANTIOXIDANTS/HOMOCYSTEINE**

Vitamin A, E, B<sub>6</sub>, folate → no change or ↑ outcomes

It's all about the numbers



# Radio, TV, and Newspaper Reports

“Aspirin produces a 30% reduction in heart attacks”

“Treating high blood pressure reduces the chance of strokes by 40%”

“Cholesterol lowering drug decreases chance of heart attacks by 35%”

“Vasectomies increase chance of prostate cancer by 40%”

Imagine that you just found out you have a risk factor for cardiovascular disease (e.g., high blood pressure or high cholesterol).

A drug that will treat this risk factor is available and it has no side effects and its cost is covered by a plan.

**Consider the following three scenarios.**

Would you be willing to take this drug every day for the next five years if it had been shown in a clinical trial that:

1) patients treated with this cholesterol pill had been shown to have **33%** fewer heart attacks than the non-treated patients; or if

2) it was found that **2%** of the patients who took this cholesterol pill had a heart attack, compared to **3%** who did not take this pill - a difference of **1%**; or if

3) in 100 patients who took this cholesterol pill for five years the medicine would prevent **one of the 100** from having a heart attack. There is no way of knowing in advance which person that might be?

# Be Wary of the “Relatives”


Anyone who says that “an event” was reduced by a number greater than 10% is almost always talking about a relative reduction

Numbers greater than 10% are misleading **unless** they are put into the proper context

Winning the Fight  
Against Silent Killers:  
High Blood Pressure and Diabetes

## Cholesterol – The Silent Killer

Become a supporter member and help us prevent premature and avoidable deaths





**25%  
OFF** = **2%  
OFF**

8% risk of a heart attack - get rid of 25% of the 8%

8% goes down to 6% = a difference of 2%

2% = 2/100 or 1/50



# What you need to ask your health care provider

NOT - how is my blood pressure/cholesterol/glucose/bone density

What is my risk of getting outcomes such as

heart attacks  
strokes  
kidney problems  
fractures


Don't want to hear "low risk" or "high risk" but rather a ballpark idea of your risk with numbers

EG: Roughly a 10% chance of having a heart attack or stroke in the next 10 years



# Cardiovascular disease

(blood pressure, cholesterol, diabetes)



10 -year baseline risk of cardiovascular disease if you are a 60 y/o female  
systolic blood pressure of 150 mmHg, non-smoker, total cholesterol of 5 and HDL 1.4

Age

60 years

Gender

Male ☒ Female ☐

Smoker

Yes ☐ No ☒

CVD risk is reversed after 5-10 years of no smoking

Yes ☐ No ☒

Diabetes

Yes ☐ No ☒

Systolic Blood Pressure

150 mmHg

Enter present blood pressure regardless of treatment

120 mmHg is used for baseline risk

On treatment for BP

Yes ☐ No ☒

Click YES if taking blood pressure medication

Total Cholesterol

5 mmol/L

Cholesterol should be prior to drug treatment

3 mmol/L is used for baseline risk.  
[Click to change to mg/dL.](#)

HDL Cholesterol

1.4 mmol/L

HDL should be prior to drug treatment

1.3 mmol/L is used for baseline risk.

Relative Benefit: 0%

Benefit often has *nothing* to do with the effect on the surrogate marker. At present, you can only select one intervention at a time.

Physical Activity

Mediterranean Diet vs Low fat

Vitamin/Omega-3 supplements

BP meds (not atenolol/doxazosin)

Low-mod intensity statins

High intensity statins

Fibrates

Niacin

Ezetimibe

Metformin

Sulfonyleureas

Insulins

Glitazones

GLPs

DPP-4s

Meglitinides

SGLT2

Smoking Cessation

ASA

[Benefit Estimate Details](#)

Risk Time Period

10 years

90.1% No event

9.9% Total with an event

0.0% Number who benefit from treatment

NNT ∞ Number needed to treat

5.5% Baseline events using baseline factors alone

4.4% Additional events "caused" by risk factors

As with all risk calculators, calculated risk numbers are +/- 5% at best. [More information.](#)

Print Report

Your baseline risk of a heart attack or stroke is 10% over the next 10 years

## If you eat the Mediterranean diet for 10 years

Age

60

 years

Gender

Male ☒ Female ☐

Smoker

Yes ☐ No ☒

CVD risk is reversed after 5-10 years of no smoking

Diabetes

Yes ☐ No ☒

Systolic Blood Pressure

150

 mmHg

Enter present blood pressure regardless of treatment  
120 mmHg is used for baseline risk

On treatment for BP

Yes ☐ No ☒

Click YES if taking blood pressure medication

Total Cholesterol

5

 mmol/L

Cholesterol should be prior to drug treatment  
3 mmol/L is used for baseline risk.  
[Click to change to mg/dL.](#)

HDL Cholesterol

1.4

 mmol/L

HDL should be prior to drug treatment  
1.3 mmol/L is used for baseline risk.

Relative Benefit: 30%

Benefit often has *nothing* to do with the effect on the surrogate marker. At present, you can only select one intervention at a time.

Physical Activity

Mediterranean Diet vs Low fat

Harm Of Intervention

No real harms

Vitamin/Omega-3 supplements

BP meds (not atenolol/doxazosin)

Low-mod intensity statins

High intensity statins

Fibrates

Niacin

Ezetimibe

Metformin

Sulfonylureas

Insulins

Glitazones

GLPs

DPP-4s

Meglitinides

SGLT2

Smoking Cessation

ASA

[Benefit Estimate Details](#)

Risk Time Period

10 years

90.1% No event

6.9% Total with an event

3.0% Number who benefit from treatment

NNT 34 Number needed to treat

5.5% Baseline events using baseline factors alone

1.4% Additional events "caused" by risk factors

As with all risk calculators, calculated risk numbers are +/- 5% at best. [More information.](#)

Print Report

Risk goes from 10% down to 7%

## If you are physical active over 10 years

Age

60

 years

Gender

Male ☐ Female ☒

Smoker

Yes ☐ No ☒

CVD risk is reversed after 5-10 years of no smoking

Diabetes

Yes ☐ No ☒

Systolic Blood Pressure

150

 mmHg

Enter present blood pressure regardless of treatment  
120 mmHg is used for baseline risk

On treatment for BP

Yes ☐ No ☒

Click YES if taking blood pressure medication

Total Cholesterol

5

 mmol/L

Cholesterol should be prior to drug treatment  
3 mmol/L is used for baseline risk.  
[Click to change to mg/dL.](#)

HDL Cholesterol

1.4

 mmol/L

HDL should be prior to drug treatment  
1.3 mmol/L is used for baseline risk.

Relative Benefit: 25%

Benefit often has *nothing* to do with the effect on the surrogate marker. At present, you can only select one intervention at a time.

Physical Activity

Harm Of Intervention

Potential for activity-related injury

Additional Benefits

- Less depression
- Improves sleep quality
- Improves OA pain and function

Mediterranean Diet vs Low fat

Vitamin/Omega-3 supplements

BP meds (not atenolol/doxazosin)

Low-mod intensity statins

High intensity statins

Fibrates

Niacin

Ezetimibe

Metformin

Sulfonylureas

Insulins

Glitazones

GLPs

DPP-4s

Meglitinides

SGLT2


Smoking Cessation

ASA

[Benefit Estimate Details](#)

Risk Time Period

10 years



90.1%

 No event

7.4%

 Total with an event

2.5%

 Number who benefit from treatment

NNT 40

 Number needed to treat

5.5%

 Baseline events using baseline factors alone

1.9%

 Additional events "caused" by risk factors

As with all risk calculators, calculated risk numbers are +/- 5% at best. [More information.](#)

Print Report

Risk goes from 10% down to 8%

## If you treat the blood pressure for 10 years

Age

years

Gender

☐ Male ☒ Female

Smoker

☐ Yes ☒ No

CVD risk is reversed after 5-10 years of no smoking

Diabetes

☐ Yes ☒ No

Systolic Blood Pressure

mmHg

Enter present blood pressure regardless of treatment  
120 mmHg is used for baseline risk

On treatment for BP

☐ Yes ☒ No

Click YES if taking blood pressure medication

Total Cholesterol

mmol/L

Cholesterol should be prior to drug treatment  
3 mmol/L is used for baseline risk.  
[Click to change to mg/dL.](#)

HDL Cholesterol

mmol/L

HDL should be prior to drug treatment  
1.3 mmol/L is used for baseline risk.

Relative Benefit: 30%

Benefit often has *nothing* to do with the effect on the surrogate marker. At present, you can only select one intervention at a time.

Harm Of Intervention

- Types of side effects vary between drugs
- Having to stop drug due to intolerance NNH 10
- Inconvenience of surrogate remeasurements
- Drug Cost

[Benefit Estimate Details](#)

Risk Time Period

10 years

90.1% No event

6.9% Total with an event

3.0% Number who benefit from treatment

NNT 34 Number needed to treat

5.5% Baseline events using baseline factors alone

1.4% Additional events "caused" by risk factors

As with all risk calculators, calculated risk numbers are +/- 5% at best. [More information.](#)

Risk goes from 10% down to 7%

If you take a statin for 10 years

Age

60 years

Gender

Male

Female

Smoker

Yes

No

CVD risk is reversed after 5-10 years of no smoking

Diabetes

Yes

No

Systolic Blood Pressure

150 mmHg

Enter present blood pressure regardless of treatment

120 mmHg is used for baseline risk

On treatment for BP

Yes

No

Click YES if taking blood pressure medication

Total Cholesterol

5 mmol/L

Cholesterol should be prior to drug treatment

3 mmol/L is used for baseline risk.

[Click to change to mg/dL](#)

HDL Cholesterol

1.4 mmol/L

HDL should be prior to drug treatment

1.3 mmol/L is used for baseline risk.

Relative Benefit: 25%

Benefit often has *nothing* to do with the effect on the surrogate marker. At present, you can only select one intervention at a time.

Physical Activity

Mediterranean Diet vs Low fat

Vitamin/Omega-3 supplements

BP meds (not atenolol/doxazosin)

Low-mod intensity statins

Harm Of Intervention

- Muscle aches and stiffness NNH 10-20 (similar to placebo in most studies)
- Increased liver function tests (3x normal) NNH 250
- Severe muscle/kidney damage NNH 10,000
- Nausea, constipation, diarrhea
- Drug Cost

Risk Time Period

10 years

90.1% No event

7.4% Total with an event

2.5% Number who benefit from treatment

NNT 40 Number needed to treat

5.5% Baseline events using baseline factors alone


1.9% Additional events "caused" by risk factors

As with all risk calculators, calculated risk numbers are +/- 5% at best. [More information.](#)

Print Report

Risk goes from 10% down to 8%


# Shingles



## The Two Zoster Vaccines

ALL NUMBERS ADJUSTED TO 3 YEARS	Herpes zoster (shingles)		Relative benefit	Postherpetic neuralgia (pain after rash goes away)	Dose/cost
	Adults >50	Adults >70			
Placebo	2%	3.4%	~50-70%	~0.4%	1 dose \$180
Zostavax live vaccine	0.6%	1.7%		~0.2%	
Placebo	2.7%	3.5%	~90-95%	0.3%	2 doses \$250
NEW Shingrix recombinant vaccine	0.1%	0.4%		0.1%	

**BUT NO HEAD TO HEAD STUDIES**




**Tools for Practice**

Zoster Vaccine – is newer better than the old new?

**Nov 19, 2018**

Clinical Question: Is there a difference in efficacy between the new, recombinant (Shingrix®) and the live (Zostavax®) zoster vaccines?

# COVID-19



## COVID-19 Vaccine - from news releases NOT actual publications

3-4 months	Pfizer Vaccine 44,000 people (Nov 18)	Moderna Vaccine 30,000 people (Nov 16)
Placebo	162 cases/22,000 = 0.7% or 1/142	90 cases/15,000 = 0.6% or 1/167
Vaccine	8 cases/22,000 = 0.04% or 1/2,500	5 cases/15,000 = 0.03% or 1/3,000
Relative benefit	0.04% is 95% less than 0.7% = 95% benefit	0.03% is 95% less than 0.6% = 95% benefit
Absolute benefit	0.7% minus 0.04% = 0.66% benefit	0.6% minus 0.03% = 0.57% benefit
SERIOUS CASES	10 placebo and 1 vaccine	11 placebo and 0 vaccine

# It's all about figuring out

The Chance of “X”

WITH NO  
TREATMENT/TEST

The Chance “X”

WITH  
TREATMENT/TEST



think  
for  
yourself

What I hoped I achieved

HOPE



Sceptic



Cynic

DOUBT